Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals, Inc. Common Stock

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. The company's lead drug candidate, rencofilstat, is involved in reducing liver fibrosis and is currently in Phase 2 clinical development for the treatment of NASH.

Hepion Pharmaceuticals

Hepion Pharmaceuticals | 1,885 followers on LinkedIn. Hepion Pharmaceuticals, Inc. is not affiliated in any way with Wire™ or Wire Swiss GmbH in any capacity. | Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies.

COM:HEPIONPHARMA